177Lu-LNC1003 / Dongcheng Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
177Lu-LNC1003 / Dongcheng Pharma
NCT06237491: The Safety and Dosimetry Study of 177Lu-LNC1003 Injection

Not yet recruiting
1
12
NA
177Lu-LNC1003 Injection group 1, 177Lu-LNC1003 Injection group 2, 177Lu-LNC1003 Injection group 3
Yantai LNC Biotechnology Singapore PTE. LTD.
Metastatic Castration-resistant Prostate Cancer, mCRPC
11/25
12/25
NCT05613738: 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer

Recruiting
N/A
9
RoW
1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01, 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01, 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01
Peking Union Medical College Hospital
Metastatic Castration-resistant Prostate Cancer
06/25
11/25
ChiCTR2200065809: An exploratory study of 177Lu-PSMA-EB-01 in patients with prostate specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer

Recruiting
N/A
30
 
Dose 60mCi 177Lu-PSMA-EB-01 ;Dose 100mCi 177Lu-PSMA-EB-01
The Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University, Self-funded
prostate cancer
 
 

Download Options